Cytokinetics (CYTK.US) experienced a sharp increase of more than 20% during early trading on Tuesday, reaching its highest price this year at $79.72. The surge followed the company's announcement of positive preliminary results from its pivotal Phase 3 ACACIA-HCM trial, which met both primary endpoints. The study evaluated aficamten in symptomatic non-obstructive hypertrophic cardiomyopathy patients. This cardiac condition involves thickened heart muscle leading to symptoms like shortness of breath, fatigue and chest pain without significant blood flow obstruction. Trial data demonstrated statistically significant improvements versus placebo in both Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) and peak exercise performance, driving the stock's upward movement. Cytokinetics confirmed ACACIA-HCM achieved dual primary endpoints with significant improvements from baseline to week 36. Statistically meaningful enhancements were also observed versus placebo in key secondary endpoints, including proportion of participants with improved New York Heart Association functional class, composite z-score of ventilatory efficiency and pVO2, and NT-proBNP levels.